Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Hls Therapeutics Inc (HLS.TO)

Hls Therapeutics Inc (HLS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
HLS Therapeutics Announces Q3 2024 Financial Results

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric...

HLS.TO : 3.87 (+3.20%)
Stocks in play: HLS Therapeutics Inc.

Will release its Q3 fiscal 2024 financial results on Thursday, November 7. The Company will hold a conference ...

HLS.TO : 3.87 (+3.20%)
HLS Therapeutics to Host Q3 Fiscal 2024 Financial Results Conference Call

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 fiscal 2024 financial results on Thursday, November 7,...

HLS.TO : 3.87 (+3.20%)
Stocks in play: HLS Therapeutics Inc.

Announces that CEO Craig Millian, Chief Executive Officer, will present at H.C. Wainwright's 26th Annual ...

HLS.TO : 3.87 (+3.20%)
HLS Therapeutics to Present at H.C. Wainwright's 26th Annual Global Investment Conference

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric...

HLS.TO : 3.87 (+3.20%)
HLS Therapeutics Announces Q2 2024 Financial Results

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric...

HLS.TO : 3.87 (+3.20%)
Stocks in play: HLS Therapeutics Inc.

Announces that it has entered into a Product Listing Agreement with the province of Alberta, for the ...

HLS.TO : 3.87 (+3.20%)
HLS Announces Reimbursement for Vascepa® under Alberta's Provincial Drug Plan

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric...

HLS.TO : 3.87 (+3.20%)
Stocks in play: HLS Therapeutics Inc.

Will release its Q2 fiscal 2024 financial results on Thursday, August 8. The Company will hold a conference ...

HLS.TO : 3.87 (+3.20%)
HLS Therapeutics to Host Q2 Fiscal 2024 Financial Results Conference Call

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 fiscal 2024 financial results on Thursday, August 8,...

HLS.TO : 3.87 (+3.20%)

Barchart Exclusives

Should You Buy This Hot Data Center Stock Before 2024 Ends?
Wall Street rates this AI stock a “Strong Buy” because Nvidia backs it. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar